The investigators will nationally investigate the prevalence of Transthyretin Amyloidosis wildtype (ATTRwt) in patients of ≥ 65 years with left ventricular hypertrophy who present with high degree atrioventricular block (AV-block) and are admitted for pacemaker implantation. The investigators aim to characterize the group of patients with positive screening of ATTR and compare the ATTRwt disease stage at time of diagnosis for patients identified with ATTR at screening with a control group of routinely clinically diagnosed ATTRwt patients.
Study Type
OBSERVATIONAL
Enrollment
170
Bloodtest: Troponin I, NT-pro-BNP, electrolyte status, renal function, kampda/lambda free chain + ratio, M-komponent. DPD-scintigraphy. (Echocardiography)
Department of Cardiology, Aarhus University Hospital
Aarhus, Denmark
RECRUITINGDiagnosis of ATTRwt in study cohort.
Number of participants with a diagnosis of ATTRwt in the study cohort based on DPD-scintigraphy or if necessary, a cardiac biopsy.
Time frame: 3 years
Characteristics of patients with ATTRwt
Echocardiographic (Left ventricular (LV) wall thickness, LV cavity dimension, EF, GLS, diastolic function, Right Ventricular (RV) systolic function, valve disease) Biochemical profile (Troponin I, NT-pro-BNP, Renal Function (E-GFR) ), presence or history of spinal stenosis, carpal tunnel syndrome
Time frame: 3 years
Clinical Stage of time of diagnosis in patients with ATTRwt
Gilmore Staging
Time frame: 3 years
Number of heart-failure associated hospitalization among ATTRwt patients
Time frame: 5 years
All-cause mortality among ATTRwt patients.
Time frame: 5 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.